论文部分内容阅读
目的探讨ＨＡＥ方案联合治疗高危和难治性急性非淋巴细胞白血病的效果。方法成人ＡＮＬＬ２４例，其中慢粒急变５例，复发和难治性１３例，初治的高危患者６例。治疗方案：三尖杉酯碱（３～４）ｍｇ／ｄ、Ａｒａ－Ｃ２００ｍｇ／ｄ，ＶＰ１６或ＶＭ２６１００ｍｇ／ｄ，三种药物均静脉滴注１ｄ～５ｄ或７ｄ为一疗程；同时预防感染和出血。结果总的完全缓解率（ＣＲ）８０％（１９／２４），达完全缓解平均需要１．３疗程，需时３０ｄ；感染发生率８７．５％，白细胞低于１．０×１０９／Ｌ占６８％，恢复至３．０×１０９／Ｌ以上平均需要２３ｄ，血小板＞５０×１０９／Ｌ平均需要１７ｄ，无因副作用而死亡者。结论ＨＡＥ方案能明显提高高危和难治性成人ＡＮＬＬ的ＣＲ率，骨髓抑制明显，毒性能够耐受。
Objective To investigate the effect of HAE regimen in the treatment of high-risk and refractory acute non-lymphocytic leukemia. METHODS: A total of 24 adult ANLL patients were identified, including 5 cases of CRM, 13 cases of relapse and refractory disease, and 6 cases of newly diagnosed high-risk patients. Treatment program: harringtonine (3 ~ 4) mg / d, Ara-C 200mg / d, VP16 or VM26100mg / d, three drugs are intravenously 1d ~ 5d or 7d for a course of treatment; while preventing infection and bleeding . Results The total complete remission rate (CR) was 80% (19/24). On average, 1.3 courses of treatment were needed for complete remission, which took 30 days; the infection rate was 87.5%, and WBC was less than 1.0×109/L. At 68%, it took an average of 23 days to recover to 3.0 x 109/L or more, platelets >50 x 109/L took an average of 17 days, and there was no death due to side effects. Conclusions The HAE regimen can significantly increase the CR rate of high-risk and refractory adult ANLL with significant bone marrow suppression and toxicity tolerance.